KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Amortization of Deferred Charges: 2009-2024

Historic Amortization of Deferred Charges for Pacira BioSciences (PCRX) over the last 8 years, with Dec 2024 value amounting to $3.1 million.

  • Pacira BioSciences' Amortization of Deferred Charges fell 25.48% to $626,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.2 million, marking a year-over-year increase of 6.64%. This contributed to the annual value of $3.1 million for FY2024, which is 4.47% up from last year.
  • According to the latest figures from FY2024, Pacira BioSciences' Amortization of Deferred Charges is $3.1 million, which was up 4.47% from $3.0 million recorded in FY2023.
  • Pacira BioSciences' Amortization of Deferred Charges' 5-year high stood at $4.4 million during FY2022, with a 5-year trough of $2.2 million in FY2020.
  • In the last 3 years, Pacira BioSciences' Amortization of Deferred Charges had a median value of $3.1 million in 2024 and averaged $3.5 million.
  • As far as peak fluctuations go, Pacira BioSciences' Amortization of Deferred Charges spiked by 59.77% in 2022, and later crashed by 31.91% in 2023.
  • Yearly analysis of 5 years shows Pacira BioSciences' Amortization of Deferred Charges stood at $2.2 million in 2020, then increased by 27.74% to $2.8 million in 2021, then soared by 59.77% to $4.4 million in 2022, then plummeted by 31.91% to $3.0 million in 2023, then climbed by 4.47% to $3.1 million in 2024.